PF-Atlas › Clinical Trials › NCT05424887
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
AK3280 · Phase 2
Registry ID
NCT05424887
Phase
Phase 2
Status
Unknown
Drug / intervention
AK3280
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Start
2022-07
Enrollment
105
Locations
1
About this trial
This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the placebo control group.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05424887 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.